{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:19:51Z","timestamp":1792876791248,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"UK Medical Research Council research grant","award":["MR\/X011372\/1"],"award-info":[{"award-number":["MR\/X011372\/1"]}]},{"name":"UK Medical Research Council research grant","award":["MR\/X011372\/1"],"award-info":[{"award-number":["MR\/X011372\/1"]}]},{"name":"UK Medical Research Council research grant","award":["MR\/X011372\/1"],"award-info":[{"award-number":["MR\/X011372\/1"]}]},{"name":"UK Medical Research Council research grant","award":["MR\/X011372\/1"],"award-info":[{"award-number":["MR\/X011372\/1"]}]},{"name":"UK Medical Research Council research grant","award":["MR\/X011372\/1"],"award-info":[{"award-number":["MR\/X011372\/1"]}]},{"name":"National Institute for Health Research Fellowship","award":["NIHR301445"],"award-info":[{"award-number":["NIHR301445"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Statins are prescribed to lower LDL cholesterol. Clinical guidelines recommend 30\u201350% reduction within 3\u00a0months, yet many patients do not achieve this. We investigated predictors of LDL-c reduction, treatment adherence, and adverse clinical outcomes in a sample of UK Biobank participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed 76,000 UK Biobank participants prescribed atorvastatin or simvastatin in primary care: 41,000 had LDL-c measurements before statin initiation (median\u2009=\u200916\u00a0days prior, IQR\u2009=\u200928) and within a year of starting treatment (median\u2009=\u200989\u00a0days, IQR\u2009=\u2009125). Adherence was defined as the \u201cproportion of days covered\u201d (PDC). We estimated associations between PDC within 1\u00a0year of statin initiation, genetic factors, post-treatment LDL-c reduction, and clinical adverse outcomes. For 13,000 patients with\u2009\u2265\u20093 LDL-c measures, we used inverse probability of treatment weighting methods to estimate the effect of sustained adherence intervention on LDL-c reduction longitudinally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      LDL-c reduction following statin initiation was predicted by time until the 1st measurement (up to 26% greater reduction if returned\u2009\u2264\u20093\u00a0months vs\u2009&gt;\u20093\u00a0months), PDC (up to 38% reduction when PDC\u2009&gt;\u200995% [high] vs. 15% when PDC\u2009&lt;\u200950% [low]), and the pharmacogenetic variant\n                      <jats:italic>SLCO1B1<\/jats:italic>\n                      *5 (lowest reduction in CC-allele: 37% versus TT-allele: 39.5%). Longitudinal causal modelling showed that the most recent PDC measure exerted the largest influence on overall LDL-c reduction, followed by the initial PDC.\n                    <\/jats:p>\n                    <jats:p>\n                      Genetic predictors of reduced PDC included liability to schizophrenia (Coef\n                      <jats:sub>top 20%<\/jats:sub>\n                      \u2009\u2212\u20091.94, 95%CI\u2009\u2212\u20092.69 to\u2009\u2212\u20091.19), while genetic liability to cardiovascular diseases increased PDC (Coef\n                      <jats:sub>top 20%<\/jats:sub>\n                      1.30, 95%CI 0.55 to 2.05). High PDC was associated with increased risk of incident iron deficiency anaemia (HR 1.30, 95%CI 1.09\u20131.54) and cataract (HR 1.20, 95%CI 1.07\u20131.34), and decreased risk of incident coronary heart disease (HR 0.78, 95%CI 0.73\u20130.84).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We identify substantial variability in the time to first on-treatment LDL-c measurements and also in adherence to statin medication, highlighting a gap between NHS guidelines, LDL-c monitoring, and statin adherence. We show its subsequent impact on long-term health, demonstrating the potential effect of targeted interventions to improve adherence. We identify important predictors of reduced statin effectiveness, including pharmacogenetic variants, polygenic scores, but most of all, adherence. Tailored statin therapy strategies with patient education on statin indication and adherence could optimize treatment efficacy, safety, and long-term clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-025-04228-2","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T12:54:09Z","timestamp":1753188849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data"],"prefix":"10.1186","volume":"23","author":[{"given":"Deniz","family":"T\u00fcrkmen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A. H.","family":"Masoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipender","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke C.","family":"Pilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"25","key":"4228_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019. J Am Coll Cardiol. 2020;76(25):2982\u20133021.","journal-title":"J Am Coll Cardiol"},{"key":"4228_CR2","unstructured":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins - PubMed. Available from:\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/16214597\/."},{"key":"4228_CR3","unstructured":"Recommendations | Cardiovascular disease: risk assessment and reduction, including lipid modification | Guidance | NICE. NICE; 2023. Available from:\u00a0https:\/\/www.nice.org.uk\/guidance\/ng238\/chapter\/recommendations#assessing-response-to-treatment-5."},{"key":"4228_CR4","doi-asserted-by":"crossref","unstructured":"Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American Heart association\/American college of cardiology joint committee on clinical practice guidelines. Circulation. 2023;148(9):e9\u2013119. Available from:\u00a0https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000001168.","DOI":"10.1161\/CIR.0000000000001183"},{"key":"4228_CR5","doi-asserted-by":"crossref","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e596\u2013646. Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000000678.","DOI":"10.1161\/CIR.0000000000000725"},{"key":"4228_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140\u2013205.","journal-title":"Atherosclerosis"},{"issue":"14","key":"4228_CR7","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","volume":"80","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, et al. ACc expert consensus decision pathway on the role of nonstatin therapies for ldl-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2022;80(14):1366\u2013418.","journal-title":"J Am Coll Cardiol"},{"key":"4228_CR8","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (Ctt) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet. 2010;376(9753):1670\u201381.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"4228_CR9","doi-asserted-by":"crossref","unstructured":"Wilkinson MJ, Lepor NE, Michos ED. Evolving management of low-density lipoprotein cholesterol: a personalized approach to preventing atherosclerotic cardiovascular disease across the risk continuum. J Am Heart Assoc. 2023;12(11).","DOI":"10.1161\/JAHA.122.028892"},{"key":"4228_CR10","doi-asserted-by":"crossref","unstructured":"Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3534845\/.","DOI":"10.1007\/s11883-012-0291-7"},{"key":"4228_CR11","doi-asserted-by":"crossref","unstructured":"Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM, et al. Medication adherence: a call for action. Am Heart J. 2011;162(3):412\u201324. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870311004753.","DOI":"10.1016\/j.ahj.2011.06.007"},{"issue":"3","key":"4228_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","volume":"4","author":"F Rodriguez","year":"2019","unstructured":"Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019;4(3):206.","journal-title":"JAMA Cardiol"},{"key":"4228_CR13","doi-asserted-by":"crossref","unstructured":"Hirsh BJ, Smilowitz NR, Rosenson RS, Fuster V, Sperling LS. Utilization of and adherence to guideline-recommended lipid-lowering therapy after acute coronary syndrome: opportunities for improvement. J Am Coll Cardiol. 2015;66(2):184\u201392. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0735109715024754.","DOI":"10.1016\/j.jacc.2015.05.030"},{"key":"4228_CR14","doi-asserted-by":"publisher","unstructured":"de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromesphase z of the a to z trial. JAMA. 2004;292(11):1307\u201316. Available from: https:\/\/doi.org\/10.1001\/jama.292.11.1307.","DOI":"10.1001\/jama.292.11.1307"},{"issue":"6","key":"4228_CR15","first-page":"459","volume":"16","author":"RE Aubert","year":"2010","unstructured":"Aubert RE, Yao J, Xia F, Garavaglia SB. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care. 2010;16(6):459\u201366.","journal-title":"Am J Manag Care"},{"issue":"22","key":"4228_CR16","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1161\/CIRCULATIONAHA.116.024436","volume":"135","author":"P Natarajan","year":"2017","unstructured":"Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation. 2017;135(22):2091\u2013101.","journal-title":"Circulation"},{"issue":"9984","key":"4228_CR17","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/S0140-6736(14)61730-X","volume":"385","author":"JL Mega","year":"2015","unstructured":"Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. The Lancet. 2015;385(9984):2264\u201371.","journal-title":"The Lancet"},{"issue":"5","key":"4228_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cpt.2557","volume":"111","author":"RM Cooper-DeHoff","year":"2022","unstructured":"Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin Pharmacol Ther. 2022;111(5):1007\u201321.","journal-title":"Clin Pharmacol Ther"},{"key":"4228_CR19","doi-asserted-by":"crossref","unstructured":"T\u00fcrkmen D, Masoli JAH, Kuo C, Bowden J, Melzer D, Pilling LC. Statin treatment effectiveness and the SLCO1B1 *5 reduced function genotype: Long\u2010term outcomes in women and men. Br J Clin Pharmacol. 2022;88(7):3230\u201340. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15245.","DOI":"10.1111\/bcp.15245"},{"key":"4228_CR20","doi-asserted-by":"crossref","unstructured":"Cordioli M, Corbetta A, Kariis HM, Jukarainen S, Vartiainen P, Kiiskinen T, et al. Socio-demographic and genetic risk factors for drug adherence and persistence across 5 common medication classes. Nat Commun. 2024;15(1):9156. Available from: https:\/\/www.nature.com\/articles\/s41467-024-53556-z.","DOI":"10.1038\/s41467-024-53556-z"},{"key":"4228_CR21","doi-asserted-by":"crossref","unstructured":"Sadler MC, Apostolov A, Cevallos C, Ribeiro DM, Altman RB, Kutalik Z. Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medications. 2024. Available from: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.04.06.24305415.","DOI":"10.1101\/2024.04.06.24305415"},{"key":"4228_CR22","doi-asserted-by":"crossref","unstructured":"Olarte Parra C, Daniel RM, Bartlett JW. Hypothetical estimands in clinical trials: a unification of causal inference and missing data methods. Stat Biopharm Res. 2023;15(2):421\u201332. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19466315.2022.2081599.","DOI":"10.1080\/19466315.2022.2081599"},{"key":"4228_CR23","doi-asserted-by":"crossref","unstructured":"Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and\/or Hypertriglyceridemia. JAMA Cardiol. 2020;5(5):540. Available from: https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2761953.","DOI":"10.1001\/jamacardio.2020.0013"},{"key":"4228_CR24","doi-asserted-by":"crossref","unstructured":"Casanova F, Tian Q, Atkins JL, Wood AR, Williamson D, Qian Y, et al. Iron and risk of dementia: mendelian randomisation analysis in UK biobank. J Med Genet. 2024;jmg-2023\u2013109295. Available from: https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmg-2023-109295.","DOI":"10.1136\/jmg-2023-109295"},{"key":"4228_CR25","doi-asserted-by":"crossref","unstructured":"Thompson DJ, Wells D, Selzam S, Peneva I, Moore R, Sharp K, et al. UK biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and quantitative traits. 2022. Available from: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.06.16.22276246.","DOI":"10.1101\/2022.06.16.22276246"},{"key":"4228_CR26","doi-asserted-by":"crossref","unstructured":"Murrin O, Mounier N, Voller B, Tata L, Gallego-Moll C, Roso-Llorach A, et al. A systematic analysis of the contribution of genetics to multimorbidity and comparisons with primary care data. eBioMedicine. 2025;113:105584.","DOI":"10.1016\/j.ebiom.2025.105584"},{"key":"4228_CR27","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1038\/ncomms6068","volume":"5","author":"I Postmus","year":"2014","unstructured":"Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014;5:5068.","journal-title":"Nat Commun"},{"issue":"4","key":"4228_CR28","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1017\/S0003055418000357","volume":"112","author":"M Blackwell","year":"2018","unstructured":"Blackwell M, Glynn AN. How to make causal inferences with time-series cross-sectional data under selection on observables. Am Polit Sci Rev. 2018;112(4):1067\u201382.","journal-title":"Am Polit Sci Rev"},{"issue":"5","key":"4228_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hern\u00e1n MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiol Camb Mass. 2000;11(5):550\u201360.","journal-title":"Epidemiol Camb Mass"},{"key":"4228_CR30","doi-asserted-by":"crossref","unstructured":"Fong C, Hazlett C, Imai K. Covariate balancing propensity score for a continuous treatment: Application to the efficacy of political advertisements. Ann Appl Stat. 2018;12(1). Available from: https:\/\/projecteuclid.org\/journals\/annals-of-applied-statistics\/volume-12\/issue-1\/Covariate-balancing-propensity-score-for-a-continuous-treatment--Application\/10.1214\/17-AOAS1101.full.","DOI":"10.1214\/17-AOAS1101"},{"key":"4228_CR31","doi-asserted-by":"crossref","unstructured":"Austin PC. Assessing covariate balance when using the generalized propensity score with quantitative or continuous exposures. Stat Methods Med Res. 2019;28(5):1365\u201377. Available from: https:\/\/journals.sagepub.com\/doi\/10.1177\/0962280218756159.","DOI":"10.1177\/0962280218756159"},{"key":"4228_CR32","doi-asserted-by":"crossref","unstructured":"Bishop CD, Leite WL, Snyder PA. Using propensity score weighting to reduce selection bias in large-scale data sets. J Early Interv. 2018;40(4):347\u201362. Available from: https:\/\/journals.sagepub.com\/doi\/10.1177\/1053815118793430.","DOI":"10.1177\/1053815118793430"},{"key":"4228_CR33","doi-asserted-by":"crossref","unstructured":"Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat Genet. 2021;53(7):1097\u2013103. Available from: https:\/\/www.nature.com\/articles\/s41588-021-00870-7.","DOI":"10.1038\/s41588-021-00870-7"},{"key":"4228_CR34","doi-asserted-by":"crossref","unstructured":"Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203\u20139. Available from: http:\/\/www.nature.com\/articles\/s41586-018-0579-z.","DOI":"10.1038\/s41586-018-0579-z"},{"issue":"10021","key":"4228_CR35","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0140-6736(15)60865-0","volume":"387","author":"A Lopez","year":"2016","unstructured":"Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. The Lancet. 2016;387(10021):907\u201316.","journal-title":"The Lancet"},{"issue":"6","key":"4228_CR36","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/cpt.1557","volume":"106","author":"DF Carr","year":"2019","unstructured":"Carr DF, Francis B, Jorgensen AL, Zhang E, Chinoy H, Heckbert SR, et al. Genomewide association study of statin-induced myopathy in patients recruited using the UK clinical practice research datalink. Clin Pharmacol Ther. 2019;106(6):1353\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"4228_CR37","doi-asserted-by":"crossref","unstructured":"Forbes CA, Deshpande ,Sohan, Sorio-Vilela ,Francesc, Kutikova ,Lucie, Duffy ,Steven, Gouni-Berthold ,Ioanna, et al. A systematic literature review comparing methods for the measurement of patient persistence and adherence. Curr Med Res Opin. 2018;34(9):1613\u201325.","DOI":"10.1080\/03007995.2018.1477747"},{"key":"4228_CR38","doi-asserted-by":"crossref","unstructured":"Cordioli M, Corbetta A, Kariis HM, Jukarainen S, Vartiainen P, Kiiskinen T, et al. Socio-demographic and genetic risk factors for drug adherence and persistence: a retrospective nationwide and biobank study across 5 medication classes and 1 845 665 individuals. 2023. Available from: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.10.09.23296740.","DOI":"10.1101\/2023.10.09.23296740"},{"key":"4228_CR39","doi-asserted-by":"crossref","unstructured":"Aarnio EJ, Martikainen JA, Helin-Salmivaara A, Huupponen RK, Hartikainen JEK, Peura PK, et al. Register-based predictors of adherence among new statin users in Finland. J Clin Lipidol. 2014;8(1):117\u201325. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287413002973.","DOI":"10.1016\/j.jacl.2013.09.008"},{"issue":"5","key":"4228_CR40","first-page":"574","volume":"28","author":"M Lemstra","year":"2012","unstructured":"Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28(5):574\u201380.","journal-title":"Can J Cardiol"},{"issue":"2","key":"4228_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.15386\/mpr-1201","volume":"92","author":"LA Anghel","year":"2019","unstructured":"Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019;92(2):117\u201322.","journal-title":"Med Pharm Rep"},{"key":"4228_CR42","doi-asserted-by":"crossref","unstructured":"Ahn J, Lee S, Won S. Possible link between statin and iron deficiency anemia: A South Korean nationwide population-based cohort study. Sci Adv. 2023;9(43):eadg6194. Available from: https:\/\/www.science.org\/doi\/10.1126\/sciadv.adg6194.","DOI":"10.1126\/sciadv.adg6194"},{"key":"4228_CR43","doi-asserted-by":"crossref","unstructured":"Mascitelli L, Goldstein MR. Might the beneficial effects of statin drugs be related to their action on iron metabolism? QJM. 2012;105(12):1225\u20139. Available from: https:\/\/acadeamic.oup.com\/qjmed\/article-lookup\/doi\/10.1093\/qjmed\/hcs204.","DOI":"10.1093\/qjmed\/hcs204"},{"key":"4228_CR44","doi-asserted-by":"crossref","unstructured":"Zacharski LR, DePalma RG, Shamayeva G, Chow BK. The statin\u2013iron nexus: anti-inflammatory intervention for arterial disease prevention. Am J Public Health. 2013;103(4):e105. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3673278\/.","DOI":"10.2105\/AJPH.2012.301163"},{"key":"4228_CR45","doi-asserted-by":"crossref","unstructured":"Yu S, Chu Y, Li G, Ren L, Zhang Q, Wu L. Statin Use and the Risk of Cataracts: A Systematic Review and Meta\u2010Analysis. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2017;6(3):e004180. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5523994\/.","DOI":"10.1161\/JAHA.116.004180"},{"key":"4228_CR46","doi-asserted-by":"crossref","unstructured":"Bowden J, Madsen J, Goldman B, Iversen AT, Liang X, Vansteelandt S. Instrumental Variable methods to target Hypothetical Estimands with longitudinal repeated measures data: Application to the STEP 1 trial. arXiv; 2024. Available from: http:\/\/arxiv.org\/abs\/2407.02902.","DOI":"10.1002\/sim.70076"},{"key":"4228_CR47","doi-asserted-by":"crossref","unstructured":"Bowden J, Pilling LC, T\u00fcrkmen D, Kuo CL, Melzer D. The Triangulation WIthin a STudy (TWIST) framework for causal inference within pharmacogenetic research. Kutalik Z, editor. PLOS Genet. 2021;17(9):e1009783. Available from: https:\/\/dx.plos.org\/10.1371\/journal.pgen.1009783.","DOI":"10.1371\/journal.pgen.1009783"},{"key":"4228_CR48","doi-asserted-by":"crossref","unstructured":"Alver M, Kasela S, Haring L, Luitva LB, Fischer K, M\u00f6ls M, et al. Genetic predisposition and antipsychotic treatment effect on metabolic syndrome in schizophrenia: a ten-year follow-up study using the estonian biobank. Lancet Reg Health - Eur. 2024;41:100914. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776224000814.","DOI":"10.1016\/j.lanepe.2024.100914"},{"issue":"8","key":"4228_CR49","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/brain\/awac186","volume":"145","author":"E Mayerhofer","year":"2022","unstructured":"Mayerhofer E, Malik R, Parodi L, Burgess S, Harloff A, Dichgans M, et al. Genetically predicted on-statin LDL response is associated with higher intracerebral haemorrhage risk. Brain J Neurol. 2022;145(8):2677\u201386.","journal-title":"Brain J Neurol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04228-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04228-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04228-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T18:14:49Z","timestamp":1757268889000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04228-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4228"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04228-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.01.23.25321011","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The collection and use of UK Biobank data was approved by the North West Multi-Centre Research Ethics Committee (Research Ethics Committee reference 11\/NW\/0382).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"UK Biobank participants gave informed consent for their data to be used in health research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"436"}}